https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3ASGLT2_inhibitor%2F43%2FjaTranslations:SGLT2 inhibitor/43/ja - Revision history2026-07-03T18:27:42ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:SGLT2_inhibitor/43/ja&diff=114346&oldid=prevFire: Created page with "==外部リンク== * {{cite web | title=FDA revises label of diabetes drug canagliflozin | website=U.S. Food and Drug Administration | date=15 January 2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet }} * {{cite web | title=FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana,..."2024-02-13T00:17:59Z<p>Created page with "==外部リンク== * {{cite web | title=FDA revises label of diabetes drug canagliflozin | website=U.S. Food and Drug Administration | date=15 January 2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet }} * {{cite web | title=FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana,..."</p>
<p><b>New page</b></p><div>==外部リンク==<br />
* {{cite web | title=FDA revises label of diabetes drug canagliflozin | website=U.S. Food and Drug Administration | date=15 January 2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet }}<br />
* {{cite web | title=FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) | website=U.S. Food and Drug Administration | date=18 May 2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-confirms-increased-risk-leg-and-foot-amputations-diabetes-medicine }}<br />
* {{cite web | title=FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate | website=U.S. Food and Drug Administration | date=9 May 2017 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-interim-clinical-trial-results-find-increased-risk-leg-and-foot }}<br />
* {{cite web | title=Warning use metformin in certain patients with reduced kidney function | website=U.S. Food and Drug Administration | date=14 November 2017 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain }}<br />
* {{cite web | title=Warning: infection of genital area with SGLT2 inhibitors for diabetes | website=U.S. Food and Drug Administration | date=7 September 2018 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes }}</div>Fire